Can a UK life sciences start-up succeed in 2025? The odds, the traps, and how to tilt the table

The short answer

  • There isn’t a single official “life-sciences startup failure rate” for the UK. As a proxy, the Office for National Statistics shows 39.4% of UK businesses survive five years—so ~60.6% fail within five years (all sectors). Life sciences add extra technical and regulatory risk on top of that baseline. Office for National Statistics
  • The funding climate is better than 2023 but still selective: UK biotech raised £3.5bn in 2024 (up 94% YoY) and £1.23bn in H1 2025, yet investors remain choosy and much of the capital is international. Layoffs continue sector-wide.
  • Technically, drug programs are inherently risky: ~7.9% of assets that enter Phase 1 ever reach approval (global). If your company rides on a single asset, that probability drives company risk. Biotechnology Innovation Organization

So…what are your real chances?

Baseline: Treat ~40% five-year survival as a rough economy-wide benchmark. For a therapeutics startup tied to one or two clinical assets, the probability of product success (and ability to keep financing) often makes the company’s odds worse than the macro baseline—unless you spread risk (multiple shots on goal), de-risk early, and manage runway tightly. UK capital is available, but access is uneven and still “risk-off” for many investors. Office for National Statistics

The 5 biggest reasons UK life sciences startups fail

  1. They run out of cash before value-inflecting data Fundraising cycles lengthened; down/flat rounds are common; public markets remain choppy and selective. Even strong companies have faced layoffs while waiting for data or market windows to reopen. The Wall Street JournalFierce Biotech
  2. Technical/clinical attrition (“the experiment said no”) Great science still fails often—only ~7.9% of Phase-1 programs make it to approval; Phase 2 is the biggest kill-zone. Investors routinely stress “good failures” (right de-risking experiments) vs. sloppy ones. go.bio.org
  3. Regulatory & market-access friction The UK has improved MHRA speed via International Recognition Procedure (IRP)and NICE has beefed up advice services, but many startups still under-resource regulatory/HTA strategy and NHS adoption planning.
  4. Team gaps and mis-hiring Founders may underweight experienced operators in CMC, clinical, regulatory and commercial. As one investor put it, failures often come from risks “around people, markets, timelines or cash management,” not just science.
  5. Go-to-market & reimbursement misalignment Evidence packages miss payer needs; NHS pathways are engaged too late; pricing/value communication is weak—especially outside therapeutics (Dx, digital, medtech). Houlihan Lokey

5 moves that materially improve your odds (UK-specific where it matters)

  1. Hire the right people—early—and build a grown-up board Bring in leaders who’ve shipped in your modality: CMC/quality for biologics/ATMPs; clinical operations that can run UK/EU studies; a regulatory head who knows MHRA, IRP and NICE Advice; and a commercial/NHS market-access lead (for Dx/medtech/digital). Investors consistently back experienced teams; Syncona explicitly highlights execution/leadership as a determinant in portfolio outcomes, and even steps in to change CEOs when needed. Syncona
  2. Design “killer experiments” and staged financing Map the fewest, fastest experiments that answer the value-defining questions (target, mechanism, tox, manufacturability, payer-relevant endpoints). Celebrate “good failures” that stop burn early; reserve cash for the next best shot. Labiotech.eu
  3. Get proactive on regulation and market access from Day 0
  • Use MHRA’s IRPwhere appropriate to leverage approvals from trusted regulators and speed time to UK authorisation.
  • Book NICE Advice to align evidence with HTA and NHS adoption before pivotal studies. NICE
  • Work with the Health Innovation Network (the 15 regional bodies formerly AHSNs) to pilot and scale inside the NHS. The Health Innovation Network –
  1. Plan capital like a pessimist: 18–24 months runway to the next binary Triangulate with grant and non-dilutive routes (Biomedical Catalyst etc.), but assume single-digit success rates for competitive grants—helpful when they land, not a plan you bet the company on.
  2. Ride the UK’s “selective strength” in 2025 The UK raised £3.5bn in 2024 and £1.23bn in H1 2025; much is international capital with a bias toward experienced teams and clear, capital-efficient paths. Tailor your story to that reality: milestone-driven use of proceeds, realistic valuations, and syndicates that can follow on. As Syncona’s CEO put it this year, volatile markets and access-to-capital headwinds persist, so control what you can—execution and burn. BioIndustry Association+2BioIndustry Association+2Syncona

Voices from investors & sector leaders (why this all matters)

  • Sir John Bell warns the UK risks losing momentum without deeper capital and scale-up focus—despite world-class science and talent. The Times
  • BIA data show investment is “holding firm” in 2025, yet a significant share is non-UK VC, underscoring the need to appeal to global investors and to strengthen domestic pools. pharmaphorum
  • Kate Bingham has highlighted how a collaborative, enabling regulator accelerates translation—now echoed by MHRA’s IRP. Build your plan to exploit that tailwind. NHS

Bottom line for founders (and their boards)

  • Your base case (absent special advantages) is battling a ~60% five-year failure rate seen across UK businesses. Life sciences adds technical risk: most drug programs do not succeed. Office for National Statistics
  • But 2024–25 UK capital is available for credible teams with crisp milestones, de-risked plans, and NHS-savvy market access strategies. Craft your experiments, your runway, and your hiring around that reality. BioIndustry Association+1

If you’re scaling a business and would like advice and insight particularly in hiring the right people early then connect with me here on LinkedIn and we’ll start a conversation.

Ewan Jardine, Kleboe Jardine Ltd